Figure 7

Therapeutic effects and Th1, Th17 and CD4 + CD25 + Foxp3 + Treg populations in experimental autoimmune encephalomyelitis mice treated with MSCs. A) Early intravenous injection of MSCs ameliorates EAE. MSCs were injected at days 18 and 30 after immunization as shown by arrows (1 × 10⁶ MSC/mice). B) CD4⁺IL17⁺ and CD4⁺IFN-γ⁺ cells in lymph nodes. MSCs significantly reduced the percentage of Th17 cells when injected at day 18 of the disease. C) CD4⁺CD25⁺Foxp3⁺ T cells in lymph nodes. MSCs induce CD4⁺CD25⁺Foxp3⁺ cells when injected at day 18 of the disease. Control: EAE mice without treatment. MSCD18: EAE mice treated with MSCs injected 18 days post-immunization. MSCD30: EAE mice treated with MSCs injected 30 days post-immunization. * = P <0.05, compared to EAE untreated mice as control group. All the values represent means ± SED of n = 5 control condition and n = 6 for MSCs treated mice. EAE, experimental autoimmune encephalomyelitis; MSCs, mesenchymal stem cells; Th, T helper; Treg, regulatory T cells.